Leishmaniasis is a major public infectious disease caused by the genus Leishmania. No effective drug or vaccination strategy for leishmaniasis has been designed yet. Several intracellular Leishmania antigens have been recognized to serve in vaccination, ensuring long-lasting protection against Leishmania infection. Lipophosphoglican 3 (LPG3) as a member of the heat shock protein 90 family involves in the synthesis of lipophosphoglycan (LPG) and implicates in parasite virulence. Regarding the immunological properties of LPG3 particularly its N-terminal fragment, it would be considered as a favourable adjuvant in Leishmania vaccination.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopha.2017.09.061 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Natural phytochemicals reverting M2 to M1 macrophages: A novel alternative Leishmaniasis therapy.
Microb Pathog
January 2025
Immunology lab, Biotechnology & Bioengineering, Indian Institute of Advanced Research, Gandhinagar, Gujarat, 382426, India. Electronic address:
Introduction: Leishmaniasis is a tropical parasitic disease caused by the protozoan Leishmania which remains a significant global health concern with diverse clinical manifestations. Transmitted through the bite of an infected sandfly, its progression depends on the interplay between the host immune response and the parasite. The disease outcome is linked to macrophage polarisation into M1 and M2 phenotypes.
View Article and Find Full Text PDFIn vitro and in vivo leishmanicidal and trypanocidal activities of isoflavans from Tabebuia chrysantha (Jacq.) G. Nicholson timber by-products.
Exp Parasitol
January 2025
Grupo de Química Orgánica de Productos Naturales, Instituto de Química, Universidad de Antioquia-UdeA. Calle 70 # 52-21, Medellín, Colombia. Electronic address:
Cutaneous Leishmaniasis and Chagas disease are neglected tropical diseases that affect millions worldwide. Despite the high morbidity associated with these infections, current treatments are often highly toxic and are showing diminishing efficacy. Thus, new therapeutic options are urgently needed.
View Article and Find Full Text PDFEvaluation of SB-83, a 2-amino-thiophene derivative, against Leishmania species that cause visceral leishmaniasis.
Int Immunopharmacol
January 2025
Infectious Diseases Laboratory, Campus Ministro Reis Velloso, Federal University of Parnaíba Delta, 64202-020 Parnaíba, PI, Brazil. Electronic address:
Visceral leishmaniasis is a systemic disease that affects various internal organs and represents the most severe and fatal form of leishmaniasis. Conventional treatment presents significant challenges, such as prolonged management in hospital settings, high toxicity, and an increasing growing number of cases of resistance. In previous studies, our research group demonstrated the effective and selective activity of the 2-amino-thiophene derivative SB-83 in preclinical models of cutaneous leishmaniasis.
View Article and Find Full Text PDFCollection of optimizations for untargeted metabolomics analysis of Leishmania promastigotes using gas chromatography-mass spectrometry.
Talanta
January 2025
Center for Multiplatform Metabolomics Studies (CEMM) at the Institute of Chemistry, University of Sao Paulo, Sao Paulo, SP, 05508-000, Brazil. Electronic address:
There is no consensus in the literature regarding the ideal protocol for obtaining and preparing cell samples for untargeted metabolomics. Nevertheless, the procedures must be carefully evaluated for proper and reliable results for each organism under study. This work proposes a novel protocol for determining intracellular metabolites in Leishmania promastigotes and is fully optimized for application in conjunction with gas chromatography-mass spectrometry platforms.
View Article and Find Full Text PDFIdentification of a New Pentafluorosulfanyl-Substituted Chalcone with Activity Against Hepatoma and Human Parasites.
Pharmaceuticals (Basel)
January 2025
Institute of Physiology, Charité-Universitätsmedizin Berlin, Corporate Member of the Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany.
Background/objectives: New drugs are required for the treatment of liver cancers and protozoal parasite infections. Analogs of the known anticancer active and antileishmanial 2',4',6'-trimethoxychalcone SU086 were prepared and investigated.
Methods: The chalcones were prepared according to the Claisen-Schmidt condensation protocol and analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!